Parkinson’s drug therapies in the clinical trial pipeline: 2024 update
Each year, members of the Cure Parkinson’s research team collaborate with Parkinson’s research advocates and The Michael J. Fox Foundation to present an overview on the current clinical trials landscape for Parkinson’s. The 2024 report, now published in the Journal of Parkinson’s Disease (JPD), marks...
Learn more
Latest updates in the field of neurotrophic factors in Parkinson’s
Neurotrophic factors such as GDNF are still being actively investigated as a potential treatment for Parkinson’s, and alternative methods of delivery are currently being explored.
Phase 2 clinical trial of dapansutrile for Parkinson’s confirmed
Cure Parkinson’s, in partnership with Van Andel Institute, is delighted to announce funding for a Phase 2 clinical of dapansutrile, an anti-inflammatory drug, to determine whether it can slow the progression of Parkinson’s.
Moving towards a new staging system for Parkinson’s
Cure Parkinson’s has been a part of a group of Parkinson’s scientists, charity organizations, and patient advocates from around the world to help develop a new biological staging framework for Parkinson’s.
2024: research highlights of last year and the year ahead
With the announcement of some very encouraging results from completed clinical trials last year, and a number of promising new projects focused on disease modification – the outlook for 2024 is looking good!
Alpha-synuclein or Tau in Parkinson’s?
The build-up of a protein called alpha-synuclein has been considered one of the hallmarks of Parkinson’s. Recently, however, a group of scientists have called into question the ‘bad guy’ role of alpha-synuclein.